Published in Pharma Investments, Ventures and Law Weekly, July 9th, 2006
Sales for Q4 of Fiscal 2006 ending March 31, 2006 were $24.7 million as compared to $17.3 million for the corresponding period of 2005, representing sales growth of almost 43%.
Daniel H. Movens, Caraco's chief executive officer, said "The record increase in sales was primarily due to our team's continued execution of our plan, improved production and sales of our generic equivalent of Ultracet that was launched in the latter...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly